South Korea Suspends MFDS Painkiller Sales Over Labeling Breaches
7. May 2026South Korea’s Ministry of Food and Drug Safety (MFDS) has ordered a temporary sales suspension for two anti-inflammatory painkillers produced by Korea Syntex Pharmaceutical following violations related to product labeling requirements. The regulatory action highlights the importance of MFDS compliance for pharmaceutical manufacturers seeking to maintain market access in Korea. Medical products usually require MFDS certification in order to be approved for import and sale in Korea.
According to the MFDS, the affected products are Ifpen tablets and Ifpen W tablets. The authority stated that the labeling displayed on the product containers differed from the approved or officially filed information. As a result, the company received an administrative disposition on April 27, with the three-month suspension period remaining in effect until July 9.
Repeated GMP and Manufacturing Compliance Issues
The latest enforcement action follows a series of previous regulatory violations involving Korea Syntex Pharmaceutical. In December of last year, the company received another administrative disposition for failing to comply with Good Manufacturing Practice (GMP) requirements. The MFDS identified several deficiencies, including the failure to conduct raw material quality testing, insufficient validation of cleaning procedures based on the company’s own manuals, and the absence of required stability testing.
As part of that earlier case, manufacturing operations for 58 pharmaceutical items were suspended for periods ranging from three to four months. The repeated violations have drawn attention to the stricter enforcement environment surrounding pharmaceutical manufacturing and quality management in South Korea.
The MFDS continues to strengthen oversight of pharmaceutical production processes as part of broader efforts to ensure product safety, manufacturing consistency, and accurate labeling within the domestic healthcare market.
Implications for Pharmaceutical Manufacturers
Korea Syntex Pharmaceutical has also faced previous sanctions related to unauthorized formulation changes. In November 2023, regulators found that the company had added an excipient during manufacturing without approval, leading to the cancellation of its GMP compliance determination. A second cancellation occurred in April 2024 after the company was found to have changed an excipient without submitting the required change report to regulators.
The company challenged the administrative measures through legal proceedings but ultimately lost in the first trial and later accepted the ruling.
The case underscores the importance of maintaining accurate product registration details, validated manufacturing procedures, and strict GMP compliance under South Korea’s pharmaceutical regulatory framework. Manufacturers exporting or producing medical products for the Korean market may face administrative penalties, production suspensions, or certification cancellations if they fail to comply with MFDS filing and quality requirements.
Further regulatory developments may continue to influence compliance expectations for pharmaceutical companies operating in Korea’s regulated healthcare sector.
Feel free to contact us any time if you need assistance or have any questions regarding Korean certifications like KC, KC EMC, KCs, KCs for explosion safety products, KGS factory registration and MFDS for medical devices.
Tel. Europe: +49-69-271 37 69 259
Tel. US: +1 773 654-2673
Email: info@korea-certification.com
For more information you can download our free brochure “Korea Certification Made Easy – The Booklet“.
